IBL-202

Peer Review Publications:

"The dual inhibitor of the phosphoinositol‐3 and PIM kinases, IBL‐202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment"

O. Giles Best, British Journal of Haematology; 5 July 2018.

"Combination of the dual PIM/PI3-kinase inhibitor IBL-202 and venetoclax is effective in diffuse large B-cell lymphoma"

Giles Best and William Stevenson, Journal Leukemia & Lymphoma; 29 July 2020.

"IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment"

Yandong Shen O. Giles Best. Blood Adv 2020; 21st October 2020

Poster Presentations:

• "The Dual PI3/PIM-Kinase Inhibitor, IBL-202, Is Highly Synergistic with Venetoclax Against CLL Cells, and TP53-Knock-out Cells, and Under Conditions That Mimic the Tumor Microenvironment"

        2018 ASH Annual Conference, December 1-4, 2018, San Diego.

• “Dual inhibition of PIM and PI3-kinase by IBL-202 is effective against CLL cells cultured under conditions that mimic the hypoxic tumour microenvironment” 
  International Workshop on Chronic Lymphocytic Leukaemia 2015, September 7-9, 2015 in Sydney, Australia. 

• “Cotargeting of PIM, PI3K and Mtor in Mantle Cell Lymphoma (MCL)”

         57th ASH Annual Meeting, Orlando, December 5-8, 2015.

• "Initial Evaluation of Novel Dual PIM/PI3K and Triple PIM/PI3K/MTOR inhibitors in multiple myeloma"
  20th Congress of the European Hematology Association (EHA) June 11 – 14, 2015, Vienna.

• “Dual Inhibition of PIM and PI3-Kinase by IBL-202 is Highly Synergistic Compared to Mono-Molecular Inhibition and Represents a Novel Treatment Strategy for Chronic Lymphocytic Leukemia”
  56th Annual Meeting of the American Society for Haematology (ASH), December 6-9, 2014 San Francisco, California.

• “Combined inhibition of PIM and PI3 kinases shows an enhanced efficacy in a number of solid tumour cell lines”
  American Association for Cancer Research (AACR) Annual Meeting 2014, April 5-9, San Diego, California.

• “Co-targeting PIM and PI3K/mTOR pathways with a single molecule: Novel orally available combined PIM/PI3K and PIM/PI3K/mTOR kinases inhibitors”
  2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, Boston, USA.